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Abstract
Background: There is strong evidence showing that male circumcision (MC) reduces HIV infection and other sexually
transmitted infections (STIs). In Rwanda, where adult HIV prevalence is 3%, MC is not a traditional practice. The Rwanda
National AIDS Commission modelled cost and effects of MC at different ages to inform policy and programmatic decisions
in relation to introducing MC. This study was necessary because the MC debate in Southern Africa has focused primarily on
MC for adults. Further, this is the first time, to our knowledge, that a cost-effectiveness study on MC has been carried out in
a country where HIV prevalence is below 5%.
Methods and Findings: A cost-effectiveness model was developed and applied to three hypothetical cohorts in Rwanda:
newborns, adolescents, and adult men. Effectiveness was defined as the number of HIV infections averted, and was
calculated as the product of the number of people susceptible to HIV infection in the cohort, the HIV incidence rate at
different ages, and the protective effect of MC; discounted back to the year of circumcision and summed over the life
expectancy of the circumcised person. Direct costs were based on interviews with experienced health care providers to
determine inputs involved in the procedure (from consumables to staff time) and related prices. Other costs included
training, patient counselling, treatment of adverse events, and promotion campaigns, and they were adjusted for the
averted lifetime cost of health care (antiretroviral therapy [ART], opportunistic infection [OI], laboratory tests). One-way
sensitivity analysis was performed by varying the main inputs of the model, and thresholds were calculated at which each
intervention is no longer cost-saving and at which an intervention costs more than one gross domestic product (GDP) per
capita per life-year gained. Results: Neonatal MC is less expensive than adolescent and adult MC (US$15 instead of US$59
per procedure) and is cost-saving (the cost-effectiveness ratio is negative), even though savings from infant circumcision will
be realized later in time. The cost per infection averted is US$3,932 for adolescent MC and US$4,949 for adult MC. Results for
infant MC appear robust. Infant MC remains highly cost-effective across a reasonable range of variation in the base case
scenario. Adolescent MC is highly cost-effective for the base case scenario but this high cost-effectiveness is not robust to
small changes in the input variables. Adult MC is neither cost-saving nor highly cost-effective when considering only the
direct benefit for the circumcised man.
Conclusions: The study suggests that Rwanda should be simultaneously scaling up circumcision across a broad range of
age groups, with high priority to the very young. Infant MC can be integrated into existing health services (i.e., neonatal
visits and vaccination sessions) and over time has better potential than adolescent and adult circumcision to achieve the
very high coverage of the population required for maximal reduction of HIV incidence. In the presence of infant MC,
adolescent and adult MC would evolve into a ‘‘catch-up’’ campaign that would be needed at the start of the program but
would eventually become superfluous.
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Male circumcision (MC) is one of the oldest and most common
surgical procedures with approximately 30% of men circumcised
worldwide [1]. While MC is almost universal in North Africa and
most of West Africa, it is less common in Southern Africa where
HIV prevalence is much higher. In Rwanda, MC is not a
traditional procedure and it is estimated that only about 15% [2]
of men are circumcised. Nonetheless, due to the ongoing debate
about MC in the country, demand for the service is increasing
(Ministry of Health [MOH], Rwanda).
Conclusive evidence from three randomised control trials
conducted in Uganda, Kenya, and South Africa showed that
MC reduces the risk of HIV infection by about 55%: 51% in
Uganda [3], 53% in Kenya [4], and 60% in South Africa [5].
Studies also report a substantially reduced risk of other sexually
transmitted infections (STIs) among circumcised men, such as
syphilis (summary risk ratio [RR]=0.67, 95% confidence interval
[CI] 0.54–0.83) and chancroid (RR 0.12–1.11) [6]. In these
studies, the reduced risk of herpes simplex virus type 2 (HSV-2)
infection is of borderline statistical significance (summary
RR=0.88, 95% CI 0.77–1.01) [6]; however, a recent study shows
that MC significantly reduces the incidence of HSV-2 (adjusted
RR 0.72, 95% CI 0.56–0.92; p=0.008) [7]. There is also evidence
that MC protects against urinary tract infections (RR=0.13, CI
0.01–2.63) [8]; invasive penile cancer [9]; and reduces prevalence
of human papillomavirus (HPV) (adjusted RR 0.65, 95% CI 0.46–
0.90; p=0.009) [7]. Most studies report a reduced risk of
gonorrhoea and chlamydia trachomatis infection in female
partners [1]. Moreover, MC protects against balanitis, posthitis,
phimosis, and paraphimosis [9].
MC can be performed at different ages, with important
differences in complication rates. Neonatal circumcision is a
simple, quick procedure, healing within 1 wk with a low rate of
usually minor adverse events (0.2%–0.4% in the US) when
performed in clinical settings by trained professionals [10]. In
adults the procedure is more complex and usually takes 4–6 wk for
the wound to fully heal. The rate of complications (such as pain,
bleeding, infections, and/or injury) ranges from 2% to 4% when
performed under optimal conditions [10].
Adult HIV prevalence in Rwanda is 3.0% (95% CI 2.6–3.4)
[11] with HIV transmission mainly occurring through hetero-
sexual sex. Prevalence among men is 2.3%; 3.8% among
circumcised men and 2.1% among uncircumcised men [11].
However, when comparing men living in urban areas, where
seroprevalence is higher and where the majority of circumcised
men live, prevalence among circumcised men (5.0%) is lower
than among uncircumcised men (5.7%) [11]. On the basis of
these data and particularly given the conclusive evidence in
favour of MC in the randomised trials cited, the National AIDS
Commission of Rwanda (CNLS) developed a cost-effectiveness
model in order to better inform policy and programmatic
decisions about implementing a MC program in the country.
Complementary studies on knowledge, attitudes, and practice of
MC are ongoing.
A cost-effectiveness study on MC for infants and adolescents is
needed given the fact that the MC debate in Southern Africa has
focused primarily on MC for adults. Without a vaccine or cure for
AIDS available, the CNLS in Rwanda felt that strategic planning
of interventions should take a longer-term perspective and include
future generations. We hypothesize that a strategy combining
infant and adult/adolescent circumcision would be both more
cost-effective and more sustainable than circumcising only adult
men. This is the first time, to our knowledge, that a cost-
effectiveness study on MC has been carried out in a country where
HIV prevalence is below 5% [12–16].
Methods
The analysis adopts the perspective of the Government of
Rwanda as a health care payer. In the absence of available tools to
evaluate the impact of neonatal, adolescent, and adult MC, a basic
cost-effectiveness model was developed. Calculations refer to an
average Rwandan adolescent or adult male, and reflect risk factors
for HIV such as age at first intercourse and presence of STIs, as
well as sexual behaviours such as condom use and number/
concurrency of partners.
Effectiveness, defined as the number of HIV infections
averted, was calculated by projecting the reduction in HIV
incidence over time. Costs included the materials necessary for
performing circumcisions, staff time, associated staff training,
patient counselling, the treatment of adverse events, and
related promotion campaigns, and were adjusted for the averted
lifetime cost of health care (antiretroviral therapy [ART],
opportunistic infections [OIs], laboratory tests), conservatively
considering only averted HIV treatment costs, not those of
other STIs.
One-way sensitivity analysis was performed by varying the main
inputs of the model, and the thresholds at which each intervention
(a) is no longer cost-saving and (b) costs more than one GDP per
capita per life-year gained were calculated for the following
variables: discount rate, HIV incidence, protection rate of MC, the
cost of MC, the cost of health care averted, and adherence to
ART.
The model was applied to three hypothetical male cohorts in
Rwanda in 2008: newborns, adolescents, and adult men. The
number of male infants born in Rwanda in 2008 is estimated to be
approximately 210,000 (Rwanda National Institute of Statistics
[RNIS], 2009). Although only 38% of births occur in health
facilities [11], 97% of newborns receive bacille Calmette-Gue ´rin
vaccination in a health facility within 1 mo of birth (Vaccination
programme Rwanda/PEV, December 2007). This visit to a health
facility provides an opportunity to circumcise the infant, thus
making it feasible to offer circumcision to nearly all infants, of
which we estimate at least 70% are likely to undergo the
procedure. Acceptance of MC in Rwanda is expected to be high
since there are no cultural barriers to it, demand is already on the
rise (MOH, Rwanda), and the intervention is expected to be
accompanied by an intense national promotion campaign. The
numbers of circumcisions would be about 150,000 children
annually. To facilitate comparisons for this exercise, we considered
a similarly sized cohort of adolescents and of adults (there are
2,140,000 males older than 15 y in the country, RNIS), although
optimal implementation strategies should probably aim for higher
annual coverage of adolescents and adults during the initial years
of the program.
For purposes of modelling, we assumed that infants are
circumcised at birth, adolescents at age 15 y, and adults at age
30 y. The model projects HIV infections averted until death. The
average life expectancy in Rwanda is 52 y at birth, 62 y at age
15 y, and 64 y at age 30 y [17].
Effectiveness
Effectiveness is the product of the number of people susceptible
to HIV infection in the cohort, the HIV incidence rate at different
ages, and the protective effect of MC; discounted back to the year
of circumcision and summed over the life expectancy of the
circumcised men.
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analysis of effectiveness is limited to those adolescents and adults
who are HIV negative. The model includes the cost of voluntary
HIV testing and counselling (VCT) for all adolescents and adults. In
keeping with current UNAIDS recommendations [18], MC will be
offered regardless of HIV status and of whether a client accepts
VCT. MC would only be withheld if it is medically contraindicated.
For HIV prevalence, we used the rate reported in the 2005
Rwandan Demographic and Health Survey (RDHS 2005) (0.4%
for 15 y olds and 4.2% for 30-y-old men). Given the high coverage
of prevention of mother to child transmission (PMTCT) programs
in Rwanda (72% of pregnant women in need of PMTCT services
have access to them and more than 60% of all health facilities in the
country provided PMTCT services in 2008) and the Universal
Access targets the country has set for the next few years (90%
coverage by 2012) [19], we expect the proportion of children
born HIV positive to become negligible over time. Therefore,
effectiveness of MC for children is extended to the entire cohort.
Estimation of age-specific incidence rates. HIV incidence
in Rwanda in 2008 per 5-y age groups (15–19, 20–24, 25–29,
30–34, 35–39, 40–44, 45–49) was estimated using the Estimation
and Projection Package(EPP) and Spectrum software, developed by
UNAIDS and the Futures Group under the USAID Health Policy
Initiative. EPP and Spectrum are a suite of mathematical models
based on demographic (RNIS), epidemiological (RDHS 2005,
sentinel surveillance), and programmatic (ART and PMTCT,
MOH) data that are used for official HIV estimates in Rwanda.
Within the age groups, incidence was assumed as equal at each age
point. For instance, HIV incidence at 30 y of age was calculated as
total incidence for the 30–34 age group divided by 5. Total
incidence among men over the age of 15 y is assumed to be due to
insertive sexual intercourse. The infections averted for infants are
conservatively estimated because they do not include any infections
averted prior toage 15 y, asno data areavailable regardingsexually
acquired infections prior to age 15 y.
Calculation of cumulative incidence. The future, age-
specific, annual HIV incidence was assumed to remain constant at
the 2008 rate. To account for the uncertainty related to this
assumption we varied the HIV incidence rate during sensitivity
analysis. We calculated the probability for each age cohort of
becoming infected with HIV over their remaining years of life
(cumulative incidence) as the probability of getting infected in year
x0; added to the probability of getting infected in year x0+1=x1 if
not already infected in year x0 and so on.
Discounting health effects. Because health effects occur
several years in the future, following common practice in cost-
effectiveness analysis, we applied an annual discount rate of 3%
[20]. Incidence discounted to 2008 was calculated as: incidence at
age x/(1+3%)
age x and summed over each of the 5-y age periods.
Since a 3% discount rate may be low for Rwanda, higher discount
rates were used in the sensitivity analysis.
Efficacy of MC. In accordance with the randomised control
trials on MC and HIV prevention previously cited, we used an
average value of 55% for the protective effect of MC and assumed
that it was constant over the lifetime of the individual.
Calculation of infections averted. Infections averted
were calculated as HIV incidence over the 5-y age groups
multiplied per the size of the cohort and per the efficacy of MC
(55%). People already HIV positive at age 15 y and at age 30 y
received HIV testing and counselling, but were not circumcised
(150,0006[12HIV prevalence at age 15 or 30 y]). The future
stream of infections averted were discounted back to 2008.
Calculation of years of life saved. On average, the time
between HIV infection and needing treatment is 8 y [21]. For per-
person years of survival under treatment we referred to the
average life expectancy under care as reported by the US-based
Walensky study corresponding to a time in the US before
treatment of patients with multidrug resistance was available (and
approximating the situation in Rwanda today) [22]. This number
corresponds to a life expectancy of 14.9 y without discounting (in
the absence of treatment, it would only be 1.6 y from AIDS
diagnosis). In order to account for conditions in Rwanda, which
are less favourable than they were in the US (such as lower access
to second-line therapies and higher rates of competing mortality
from other causes, among others), we decreased life expectancy to
14 y on average for the base case analysis. The uncertainty of this
value is accounted for during sensitivity analysis. Thus, life years
saved are those that are lost from 8+14=22 y following infection
until that person’s life expectancy at the age of infection.
Table 1 provides a summary of the variables used to calculate
effectiveness of MC in Rwanda and shows incidence (new
infections) among men per age group.
Costs
Direct costs were modelled on the basis of interviews with
experienced health care providers and MOH officials in Kigali to
determine all inputs involved in a procedure (from staff time to
consumables) and related prices. Health care providers were asked
to base their estimates on actual cases they participated in. The
validity of the costing model was counterchecked with recently
published World Health Organization (WHO) and UNAIDS
guidelines/protocols [10].
For infants, we estimated the cost of circumcision employing the
Mogen Clamp method. The Mogen Clamp method was chosen
because it is a simple procedure that requires only one reusable
piece, does not require suturing, and causes less pain and
complications than other methods, though there is a risk of injury
if not applied carefully [10]. This method appears suitable for
national roll-out, even in remote areas.
Since the national HIV policy in Rwanda discourages vertical
programs and strongly promotes integration into existing services,
infant MC would be integrated into existing neonatal and
vaccination services and we expect no cost for infrastructure
development. Although the procedure would be integrated into
health facilities’ existing services, the complexity, time, and space
involved in adult MC will require infrastructure investment. Hence,
to circumcise 150,000 adults we accounted for 94 additional small
surgical rooms (eight procedures/day/room per 200 d/year) with a
10-y useful life. The Central Purchasing of Essential Medicines in
Rwanda (CAMERWA) and private pharmacies in Kigali provided
wholesale price quotations for consumables.
Unit costs from a recent costing exercise carried out in Rwanda
[23] were used for nonmedical inputs such as the implementation
of a nationwide promotion campaign. Additional budgeting
information from current practice in the health system was used
for calculating the cost of training staff and counselling of patients.
Costs of complications were based on calculations from a recent
publication on cost-effectiveness of adult MC in South Africa [15],
using findings from the Orange Farm MC Trial. Overall cost of
adverse events standardised to one person is US$1.03. For
children we used half of this amount (US$0.50 per MC). Given
that the frequency of side effects in children is less than half
the adult rate, and the average complication less severe, this is a
conservative estimate.
In the case of adolescents and adults we added the incremental
cost of testing and counselling for HIV (US$9.29) [24]. This value
compares well with average costs in other African countries [23]
and does not include fixed costs of installing new VCT centres.
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offered as an integrated service in Rwanda and are widely
available in the existing health centres.
A summary of costs is provided in Table 2. Details of unit costs
are available from the authors upon request. The higher cost of
MC in adolescents and adults is due to several reasons including
the higher cost of imported consumables involved in this more
complex surgical procedure (the single most expensive item being
local anaesthetic), laboratory tests, amortization costs for the
surgical kits, the cost of HIV testing and counselling, the increased
staff and staff time necessary, and the need for infrastructure scale-
up. As expected, for both children and adolescents/adults, the
costs of performing MC are below the prices currently charged by
private practitioners.
These cost estimates do not include the possibility of large
economies of scale, for instance those resulting from large orders of
supplies and equipment, or cost reduction through the judicious
use of task shifting to nurses/health workers. Since we do not know
to what level of scale economies might be attained, we account for
the possibility of lower unit costs in the context of a large-scale MC
program in the sensitivity analysis.
Savings. Savings correspond to the lifetime costs of HIV
treatment for the HIV infections averted (average number of years
of survival under treatment multiplied by the annual cost of
treatment and care), adjusted for the rate of access to treatment
and adherence.
Cost of treatment. Costs of AIDS treatment and care
include ART (first and second line), treatment for major OIs,
laboratory tests, and home-based care. Average unit costs from a
recent costing exercise carried out in Rwanda [23] were used.
Primary sources for this compilation exercise included the MOH,
TRAC Plus CIDC, CAMERWA, National Reference Laboratory,
AEDS, WHO/INSP, the Clinton Foundation, and health services
providers such as ARBEF. Table 3 provides a base case summary
of treatment and care savings per HIV infection averted. Values
are similar to those reported in the international literature for
neighbouring countries and studies in Rwanda [25].
Cohort to which apply savings. AIDS treatment costs apply
to 90% of the subcohort of people living with HIV. This percentage
was obtained assuming 95% access to ART (a realistic assumption
for Rwanda given an estimated coverage rate of 80% in 2008 and
the ambitious targets for scale-up [19].) and considering the current
high level of adherence to treatment and low losses to follow-up
[26]. Given the inevitable uncertainty related to assumptions about
future care, we varied overall cost (depending on coverage and cost
of treatment) during sensitivity analysis. We also specifically varied
the values of adherence to treatment.
Discounting savings. To calculate discounted savings,
treatment costs were multiplied by the number of discounted
infections averted and then discounted for the delay from infection
averted to averted treatment costs (8 y plus two-thirds of 14 y
average survival on treatment). Since HIV infections averted were
already discounted back to time of circumcision, we discounted
treatment costs only back to the time of the infections averted to
avoid double discounting. Treatment costs were discounted using
the same rate used for effects and as if they happened at two-thirds
between the average age at which treatment starts and death. This
assumption takes into account that ART costs are back-loaded and
most OI-related costs and home-based care occur in the years
prior to death. Table 4 presents savings and discounted savings for
the three cohorts in Rwanda.
Results
Cost-Effectiveness Results for Infants, Adolescents, and
Adult MC
Figure 1 provides total costs (unit cost of MC and HIV testing
and counselling 6150,000) and discounted savings for the
Government of Rwanda if a cohort of 150,000 people were to
be tested for HIV and circumcised in 2008.
For infant MC, total costs (US$2,250,000) are lower than
discounted total savings (US$3,808,523). Therefore, the interven-
tion is cost-saving. For adolescents and adults, total costs
(US$8,850,000) are higher than total savings, for net costs of
Table 1. Effectiveness of neonatal, adolescent, and adult MC in Rwanda, 2008.
Subgroup Variables Values Total
Age groups (y) 15–19 20–24 25–29 30–34 35–39 40–44 45–49 —
Incidence rate (cumu-
lative over the age
group) (Spectrum)
0.04% 0.08% 0.36% 0.37% 0.27% 0.33% 0.12% 1.56%
Infants (born in
2008)
Projection period 2023–27 2028–32 2033–37 2038–42 2043–47 2048–52 2053–57 —
Averted infections in
the cohort
a
31 66 294 307 222 271 97 1,288
Discounted averted
infections
19 35 132 119 74 78 24 482
Adolescents Projection period 2008–12 2013–17 2018–22 2023–27 2028–32 2033–37 2038–42 —
Averted infections 31 66 293 305 221 270 97 1,283
Discounted averted
infections
29 54 205 185 115 122 38 748
Adults Projection period ———2 0 0 8 – 1 2 2 0 1 3 – 1 7 2 0 1 8 – 2 2 2 0 2 3 – 2 7 —
Averted infections ———2 9 4 2 1 3 2 6 0 9 38 5 9
Discounted averted
infections
———2 7 7 1 7 3 1 8 2 5 66 8 9
aThe incidence rates are multiplied by cohorts of 150,000, minus the number of infections that occurred previously.
doi:10.1371/journal.pmed.1000211.t001
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tiveness ratio (net cost per infection averted) is US$3,932 and
US$4,949 for adolescents and adults, respectively.
The findings from the analysis in Rwanda show that neonatal
MC is less expensive than adolescent and adult MC (US$15
instead of US$59 per procedure) and is cost-saving; even though
Table 3. Life-time savings per each HIV infection averted.
Category of Savings per Each
HIV Infection Averted Input Values and Assumptions
Life-Time Costs per Person/
Amounts over 14 y (US$ 2008 )
Home-based care US$40 per year for counselling, medical care, clothes, nutrition, etc..).
10% of symptomatic PLHIV receive home-based care in Rwanda.
a
56
Prophylaxis and treatment of major OIs Average 3 y per person. US$160 is the WHO average treatment cost
for sub-Saharan Africa. Cost of generic for co-trimoxazole, fluconazol,
anti-TB drugs is US$122 (CAMERWA).
846
Laboratory tests including supplies 70% of patients. Average cost is US$73 per year per person (CD4,
US$8; viral load, US$25; DNA PCR US$15; hematology, US$6;
biochemistry, US$20, including reagents and all supplies plus
annualized cost of equipment), National Laboratory.
715
ART ART per person per year first line is $710 (80% of patients). TB per
year is $201 (8%), TB costs over 2 y. Cost of therapy given for toxicity
(to treat secondary effects, pregnancy, etc.) is $402 (15% patients
per 1 y). Cost of second-line therapy is $1,726 (20% of patients).
Palliative care is $267 per life-time (10% of patients).
12,890
Total Rounded amounts 14,500
90% of the cohort (to account for losses to follow-up) 13,050
aCoverage assumptions come from published literature (WHO) and routine data/consensus discussions among HIV service providers in Rwanda.
PLHIV, people living with HIV/AIDS; TB, tuberculosis.
doi:10.1371/journal.pmed.1000211.t003
Table 2. Costs standardised to one MC procedure for a cohort of 150,000 adults and 150,000 newborns in Rwanda, 2008.
Costs (Direct Costs of Procedure)
Unit Cost
Infant MC (US$)
Unit Cost Adolescent/
Adult MC (US$)
Mogen Clamp (reusable 1,000 times) 0.3 NA
Infant consumables: 1 g EMLA cream; two impregnated gauze; one absorbable
suture; 100 ml antiseptic; 1 ml glucose solution; two pairs gloves)
6.5 NA
Adolescent/adult consumables: lidocaine anaesthetic, 15 ml; suture material,
three; gauze, 15; sticking plaster; anti-inflammatory; two syringes and needles;
antiseptic; gloves masks; caps and aprons; condoms
NA 21
Surgery kit, including sterilization costs and amortization 0.6 8
Laboratory exams (bleeding time, full blood count) —6
Staff time infant: nurse A1 level (30 min plus counselling), public system 2.5 NA
Staff time adolescent/adult: surgeon and nurse (1 h plus counselling), public
system plus 15 min bandage three times every 5 d
NA 6
Programme costs
Promotion campaign (over a cohort of 150 000 people)
a 3.5 3.5
Training of health professionals, including counselling and supervision 0.8 1.3
Infrastructure costs
94 small surgical rooms (adolescent/adult) NA 2.8
Side effects 0.5 1
Subtotal 15 50
Cost of HIV testing and counselling — 9.2
TOTAL (rounded amounts) 15 59
Prices paid by clients, Kigali
Health centre starting 13
b (MOH standard) —
Private sector 45
b 87
Base case year, 2008.
aThe costs of a promotion campaign for a circumcision program that targeted infants, adolescent, and adults would be less than the sum of the individual campaigns,
which would increase the cost-effectiveness of each if implemented jointly.
bDorsal slit method (reflecting current practice in Kigali) in hospital.
doi:10.1371/journal.pmed.1000211.t002
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fact that MC of infants in Rwanda is a cost-saving intervention
means that for each MC performed, the government of Rwanda
will save money.
Still, the costs per infection averted for adolescent and adult MC
are both competitive with other HIV prevention interventions. Net
costs for adolescents are lower than for adults since circumcising
adolescents will avert a greater number of infections than
Table 4. Savings for neonatal, adolescent, and adult MC in Rwanda, 2008.
Subgroup Variables Values Total
Age groups 15–19 20–24 25–29 30–34 35–39 40–44 45–49 —
Infants Projection period 2023–27 2028–32 2033–37 2038–42 2043–47 2048–52 2053–57 —
Averted infections in
the cohort
31 66 294 307 222 271 97 1,288
Savings in US$ = lifetime cost of
treatment per person690%
adherence 6averted infections
404,550 861,300 3,836,700 4,006,350 2,897,100 3,536,550 1,265,850 16,808,400
Discounted averted infections 19 35 132 119 74 78 24 482
Discounted savings US$ = (life-
time cost of treatment per person
690% adherence 6discounted
averted infections)/([1 + 3%]
delay).
Delay = (8 + 2/3 6[14])
149,898 273,167 1,045,253 941,477 587,539 619,189 192,000 3,808,523
Adolescents Projection period 2008–12 2013–17 2018–22 2023–27 2028–32 2033–37 2038–42 —
Averted infections 31 66 293 305 221 270 97 1283
Savings US$ 404,550 861,300 3,823,650 3,980,250 2,884,050 3,523,500 1,265,850 16,743,150
Discounted averted infections 29 54 205 185 115 122 38 748
Discounted savings US$ 232,602 423,883 1,621,957 1,460,924 911,705 960,818 297,933 5,909,820
Adults Projection period — — — 2008–12 2013–17 2018–22 2023–27 —
Averted infections — — — 294 213 260 93 859
Savings US$ — — — 3,836,700 2,779,650 3,393,000 1,213,650 11,209,950
Discounted averted infections — — — 277 173 182 56 689
Discounted savings US$ — — — 2,189,564 1,366,214 1,439,811 446,460 5,442,049
doi:10.1371/journal.pmed.1000211.t004
Figure 1. Total costs and savings for neonatal, adolescent, and adult MC (cohort 150,000 people), Rwanda, 2008.
doi:10.1371/journal.pmed.1000211.g001
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greater number of years of exposure to HIV). Also, circumcising
adolescents has the potential to avert the highest number of
discounted HIV infections, because the delay from birth to
initiation of sexual activity devalues the infections prevented from
infant MC more than the ones prevented by adolescent MC.
The discounted cost per life year gained for adolescents and
adults is US$334 and US$613, respectively. To calculate the
number of life years gained, we multiplied the discounted HIV
infection averted at different ages by the life expectancy at that age
group (source: WHO Life Tables, 2006 [17]) less the years of
survival that would have in any case occurred with HIV and
treatment availability (8 y plus 14=22 y).
According to the WHO, the per-capita GDP, adjusted for the
purchase power parity of the country, can be used for setting
thresholds for cost-effectiveness. Thus, interventions for which the
additional cost incurred to gain one quality-adjusted life year is less
than the country’s per-capita GDP are considered as very cost-
effective. Considering that GDP per capita in Rwanda (based on
2007 estimates) is US$355 [27], MC for adolescents is slightly less
than one GDP/per capita/life year gained and therefore highly
cost-effective, while MC for adults is less than two GDP/per
capita/life year gained and therefore potentially cost-effective
(WHO criteria). The WHO criteria were designed to be used with
disability adjusted life years, which would increase the cost-
effectiveness ratios of adolescent and adult MC estimates here
somewhat were that adjustment to be made.
Although the extent of monetary savings are not comparable
to those associated with preventing HIV, we estimated that per
each year-cohort (150,000 persons) there will be 5,000 fewer cases
of syphilis and virtually no cases of penile cancer (one to two
cases fewer). For children, there will be at least 2,500 fewer
urinary tract infections. This finding further suggests that the
estimates presented here underestimate the cost-effectiveness of
the procedure.
Sensitivity and Thresholds Analysis
Given the uncertainty embedded in the input values of the base
case scenario, we conducted a one-way sensitivity analysis and
explored a wide rage of values in order to identify thresholds
(Table 5). We report the threshold at which the procedure costs
more than one GDP/capita/life year gained (WHO criteria for
cost-effectiveness). For infant MC we also report the threshold at
which the intervention is no longer cost-saving.
Overall, results for infant MC appear robust. However, MC for
infants is no longer cost-saving for a small increase of the discount
rate. Infant MC remains highly cost-effective across a reasonable
range of changes in the base case scenario.
To take into account the positive effects of the numerous HIV
prevention interventions ongoing in the country, we performed a
sensitivity analysis reducing the annual rate of HIV incidence from
the 2008 base case (without changing other values). We found that
the cost-effectiveness of neonatal MC is not very sensitive to a
decrease in HIV incidence, and that neonatal MC remains cost-
saving until incidence decreases 40% from the base case value,
suggesting its suitability for countries with lower HIV incidence/
prevalence.
Circumcision, and in particular adult MC, carries the potential
for risk compensation by an increase in risky sexual behaviour.
Although recent studies do not support this theory [1], we tested
our results by reducing the net protective effect of MC. Neonatal
MC is cost saving until a protective effect of MC of 33%, and
overall results for neonatal MC are relatively insensitive to a
decrease in the protective effect of MC.
Neonatal MC is cost saving up to a cost per procedure of
US$25. Understandably, since benefits will happen later in life, for
neonatal MC to remain cost saving the maximum cost per
procedure has to be lower than the cost per adolescent and adult
MC. Neonatal MC would still be highly cost-effective if the
lifetime cost of treatment and care (savings per infection averted)
fell to US$900. Because costs per MC are lower in infants, cost-
effectiveness of neonatal MC is expected to be relatively insensitive
to reduction in savings from averted treatment and care. The
sensitivity to decreases in the adherence rate to ART (or to
increased losses to follow-up) mirrors that for cost of treatment and
care. Adolescent MC is highly cost-effective for the base case
scenario but no longer so for very small changes in the input
variables. Adult MC is neither cost-saving nor highly cost-effective
in Rwanda when considering only the direct benefit of reduced
health care costs in the circumcised man.
Discussion
Infant MC can lower health system costs because of moderate
implementation costs, high and durable protective effects, and the
averted HIV-care costs. As the sensitivity analysis shows, these
findings are robust across a wide range of input values for
Rwanda. The study shows that adolescent MC may be a highly
cost-effective intervention. MC for adults is the least cost-effective
of the three procedures.
Findings are generally consistent with results from other costing
studies on adult MC in Lesotho [12], Swaziland [13], and with
cost-effectiveness analysis of adult MC in Uganda [14] and South
Table 5. Threshold analysis.
Variable Base Case
Cost-Saving
Threshold
(Infants)
Highly Cost-effective Threshold
(,1GDP/Capita/Life Year
Gained) GDP per Capita=US$355
(2007 Estimate) (Infants)
Highly Cost-effective
Threshold (,1GDP/
Capita/Life Year
Gained) (Adolescents)
Discount rate 3% 4.1% 5.4% 3.1%
HIV incidence Stable at 2008 values 40% decrease 61% decrease 2% decrease
Protective effect of MC 55% 33% 22% 54%
Cost of MC procedure US$15 infant; US$59 adult/
adolescent
US$25 US$38.50 US$60
Cost of treatment and care US$14,500 per person lifetime US$8,600 US$900 US$14,100
Adherence to treatment 90% 54% 6% 88%
doi:10.1371/journal.pmed.1000211.t005
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consequently the number of potentially averted HIV infections, is
much higher. In Uganda, with an annual HIV incidence of 1.25%
and a cost per adult MC of US$69 , the cost of MC (not adjusted
for savings on treatment) per HIV infection averted was estimated
at US$1,485 (including the indirect effect on women). The study in
South Africa shows that MC generates large net savings after
adjustment for averted HIV medical costs. With an annual HIV
incidence of 3.8% and a cost per adult MC of US$55.7, the cost of
MC (unadjusted for averted medical care costs) per HIV infection
averted was estimated at US$181 (including the indirect effect on
women); while for 1,000 circumcisions net savings (adjusted for
averted medical care cost) were US$2.4 million.
A recent study by White et al. [16] also found that MC is a
cost-saving intervention in a wide range of scenarios of HIV
and baseline circumcision prevalence. The authors predict that
circumcising neonates, although cheaper, would only become cost-
saving after around 30 y (within the time horizon of our study).
These findings are consistent with ours because our model
considers the net present value of the interventions, extended to
the entire life of the circumcised individuals. The absolute cost per
infection averted is significantly lower in the White paper than in
ours, but this is to be expected given that they estimated benefits of
reduced secondary infections among the sexual partners of the
circumcised men, while we did not. The White paper also
concludes that as neonate and adult programmes are likely to be
relatively noncompetitive for staff, facilities, and training, an
optimal strategy may be to scale up both simultaneously, which is
also consistent with our findings, albeit for a setting with much
lower incidence and prevalence.
Neonatal MC is a less expensive procedure (faster, less
complicated, and with fewer side effects) than adolescent and
adult circumcision and can also be cost-saving (even when
considering the discounting effect). Most importantly, infant
circumcision can be easily integrated into existing health services
(such as neonatal visits and vaccination sessions) and, where health
workers are well trained, it does not require skilled surgeons and
parallel structures that could drain an already weak system.
Moreover, neonatal MC may carry less risk of a compensatory
increase in risky sexual behaviour and it is likely to be more
protective than adolescent or adult circumcision because there is
no possibility of sexual activity during healing. Finally, circumci-
sion among children does not carry the same implications as those
for adolescents and adult MC, such as discomfort, stigma, and
days out of school and work (with their associated opportunity
costs).
We deduce that infant circumcision has a better potential to
achieve the very high coverage over time of the population
required to achieve maximal reduction on HIV incidence than
adolescent and adult circumcision.
This model assumes similar sized cohorts for adolescents and
adults as for infants, and one might wonder why, given that the
population in need of circumcision is so much larger than a single
birth cohort. This was done for several reasons. First, the
government policy question that prompted the study was whether
infant circumcision should be added as a strategy to that already
proposed for adolescents and adults. Thus, by using the size of the
Rwandan birth cohort, the per-person costs could be compared
with MC at other ages and the total costs and affordability of
infant MC could also be assessed. Since the model does not
attempt to estimate secondary benefits (e.g., to the female partners
of circumcised men) or the herd effect of high levels of MC, the
relative results will be the same regardless of whether the model is
run with a cohort of one or 150,000. However, while 150,000
children represent a high level of annual coverage of the birth
cohort, a realistic strategy for adolescent or adult catch-up should
probably aim for higher annual coverage. A realistic assessment of
what coverage levels could be attained, and at what cost (especially
one that considered effects of scale on program costs) goes beyond
the purpose of this study.
Given that this study does not quantify the indirect benefits of
MC, the cost-effectiveness estimates are conservative. This is likely
to be even truer for infants than for adolescents and adults for two
reasons: MC coverage of infants is likely to be much higher,
potentiating the herd effect, and, behavioural compensation is less
likely to occur with infants.
Any modelling exercise is at best an approximation of reality.
Studies that model the future, like this one, approximate a reality
that does not yet exist, and this requires making a number of
assumptions about the future (for instance on what will happen to
HIV incidence rates, on the effectiveness of large-scale circumci-
sion, and on the costs of HIV treatment in the future). Thus, these
results, like those of similar exercises, must be seen as valuable
inputs into decision-making because they identify likely impacts of
different courses of action. They cannot pretend to eliminate the
uncertainty that underlies such decisions, just to reduce it. As
mentioned above, this model also has limitations related to what it
does and does not include. The most important of these limitations
is the fact that the model only takes the prevention benefit for the
circumcised individual into consideration, and not for his sexual
partners and offspring.
Conclusions
In this study we show that MC for infants is not only highly cost-
effective but also likely to be cost-saving and that MC for
adolescents is a cost-effective procedure. Although benefits will be
gained later in life, these positive results are stronger for
circumcision of male newborns. The next step for Rwanda is to
explore how best to introduce MC at different ages, including an
appropriate mass media campaign. A pilot implementation
exercise in one district, accompanied by close monitoring and
operational research on key variables, should be followed by a
scale-up of the program country wide.
Given the low cost and long term benefits, this study suggests
that countries with moderate HIV epidemics should offer routine
infant circumcision, integrated into existing health services. In
addition, adolescents should be offered MC until aging of
circumcised infants renders it obsolete and adult MC should be
offered with priority to population groups with a high level of HIV
incidence. Owing to the increased complexity of this strategy, each
country will need to consider a variety of options to achieve high
levels of coverage with adolescent/adult MC. Options may include
specialized centres, mobile surgery units, and specialized surgery
teams that move from clinic to clinic. MC should be offered as part
of an integrated HIV prevention package that includes promotion
of safer sex (delayed initiation, reduction in multiple/concurrent
partners, and access to condoms).
African leaders and development partners should stop manag-
ing the HIV response as only an emergency issue and release
themselves from a 1-y or even a 5-y planning perspective to focus
on sustainable long-term choices for countries. From a develop-
ment perspective, because infant MC is proven to be an effective
means of HIV prevention, action cannot be deferred simply
because gains will be in the distant future. National plans should
be made accordingly on the basis of the best available information,
knowing that currently there is neither a vaccine nor cure for
AIDS, while remaining open and flexible to adaptation if better
solutions arise. In the presence of infant MC, adolescent and adult
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needed at the start of the program but would eventually become
superfluous upon attainment of high levels of infant coverage.
Infant circumcision is likely to be highly cost-effective even in
countries with lower incidence than Rwanda. In Rwanda, if the
dynamic benefits of circumcision (prevention of secondary
infections) are considered in addition to the health benefits for
the circumcised man, even adult MC is likely to be close to or
below the highly cost-effective threshold. This finding suggests that
Rwanda should be simultaneously scaling up circumcision across a
broad range of age groups, with high priority to the very young.
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Background. Acquired immunodeficiency syndrome (AIDS)
has killed more than 25 million people since 1981 and more
than 31 million people (22 million in sub-Saharan Africa
alone) are now infected with the human immunodeficiency
virus (HIV), which causes AIDS. There is no cure for HIV/AIDS
and no vaccine against HIV infection. Consequently,
prevention of HIV transmission is extremely important. HIV
is most often spread through unprotected sex with an
infected partner. Individuals can reduce their risk of HIV
infection, therefore, by abstaining from sex, by having one or
a few sexual partners, and by always using a male or female
condom. In addition, male circumcision—the removal of the
foreskin, the loose fold of skin that covers the head of
penis—can halve HIV transmission rates to men resulting
from sex with women. Thus, as part of its HIV prevention
strategy, the World Health Organization (WHO) recommends
that male circumcision programs be scaled up in countries
where there is a generalized HIV epidemic and where few
men are circumcised.
Why Was This Study Done? One such country is Rwanda.
Here, 3% of the adult population is infected with HIV but
only 15% of men are circumcised—worldwide, about 30% of
men are circumcised. Demand for circumcision is increasing
in Rwanda but, before policy makers introduce a country-
wide male circumcision program, they need to identify the
most cost-effective way to increase circumcision rates. In
particular, they need to decide the age at which circumcision
should be offered. Circumcision soon after birth (neonatal
circumcision) is quick and simple and rarely causes any
complications. Circumcision of adolescents and adults is
more complex and has a higher complication rate. Although
several studies have investigated the cost-effectiveness (the
balance between the clinical and financial costs of a medical
intervention and its benefits) of circumcision in adult men,
little is known about its cost-effectiveness in newborn boys.
In this study, which is one of several studies on male
circumcision being organized by the National AIDS Control
Commission in Rwanda, the researchers model the cost-
effectiveness of circumcision at different ages.
What Did the Researchers Do and Find? The researchers
developed a simple cost-effectiveness model and applied it
to three hypothetical groups of Rwandans: newborn
boys, adolescent boys, and adult men. For their model, the
researchers calculated the effectiveness of male circumcision
(the number of HIV infections averted) by estimating the
reduction in the annual number of new HIV infections over
time. They obtained estimates of the costs of circumcision
(including the costs of consumables, staff time, and
treatment of complications) from health care providers and
adjusted these costs for the money saved through not
needing to treat HIV in males in whom circumcision
prevented infection. Using their model, the researchers
estimate that each neonatal male circumcision would cost
US$15 whereas each adolescent or adult male circumcision
would cost US$59. Neonatal male circumcision, they report,
would be cost-saving. That is, over a lifetime, neonatal male
circumcision would save more money than it costs. Finally,
using the WHO definition of cost-effectiveness (for a cost-
effective intervention, the additional cost incurred to gain
one year of life must be less than a country’s per capita gross
domestic product), the researchers estimate that, although
adolescent circumcision would be highly cost-effective,
circumcision of adult men would only be potentially cost-
effective (but would likely prove cost-effective if the
additional infections that would occur from men to their
partners without a circumcision program were also taken
into account).
What Do These Findings Mean? As with all modeling
studies, the accuracy of these findings depends on the many
assumptions included in the model. However, the findings
suggest that male circumcision for infants for the prevention
of HIV infection later in life is highly cost-effective and likely
to be cost-saving and that circumcision for adolescents is
cost-effective. The researchers suggest, therefore, that policy
makers in Rwanda and in countries with similar HIV infection
and circumcision rates should scale up male circumcision
programs across all age groups, with high priority being
given to the very young. If infants are routinely circumcised,
they suggest, circumcision of adolescent and adult males
would become a ‘‘catch-up’’ campaign that would be
needed at the start of the program but that would
become superfluous over time. Such an approach would
represent a switch from managing the HIV epidemic as an
emergency towards focusing on sustainable, long-term
solutions to this major public-health problem.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000211.
N This study is further discussed in a PLoS Medicine
Perspective by Seth Kalichman
N Information is available from the US National Institute of
Allergy and Infectious Diseases on HIV infection and AIDS
N Information is available from the Joint United Nations
Programme on HIV/AIDS (UNAIDS) on HIV infection and
AIDS and on male circumcision in relation to HIV and AIDS
N HIV InSite has comprehensive information on all aspects of
HIV/AIDS
N Information is available from Avert, an international AIDS
charity on many aspects of HIV/AIDS, including informa-
tion on HIV and AIDS in Africa, and on circumcision and
HIV (some information in English and Spanish)
N More information about male circumcision is available
from the Clearinghouse on Male Circumcision
N The National AIDS Control Commission of Rwanda
provides detailed information about HIV/AIDS in Rwanda
(in English and French)
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